• RA患者中基质金属蛋白酶3正常和疾病活动指数小于2.6的双重达标比单一达标疗效更好:T4双标准研究


    原文

    译文

    Treating to Target Matrix Metalloproteinase 3 Normalisation Together with Disease Activity Score Below 2.6 Yields Better Effects Than Each Alone In Rheumatoid Arthritis Patients: Treating to Twin Targets; T-4 Study

     

     

    Yukitomo Urata 1, Ryoko Uesato1, Dai Tanaka1, Yoshihide Nakamura2 and Shigeru Motomura2, 1Seihoku Chuo Hospital, Gosyogawara, Japan, 2Hirosaki University Graduate School of Medicine, Hirosaki, Japan

     

    Presentation Number: 1207

     

    Background/PurposeTo assess whether therapy to achieve both disease activity score in 28 joints (DAS28) <2.6 and matrix metalloproteinase (MMP)-3 normalisation offers better outcomes than either target alone in early rheumatoid arthritis at 56 weeks; Treating to twine targets; T-4 study.

    MethodA total of 243 early RA patients were randomly allocated to one of four strategy groups: routine care (R group; n=62); DAS28-driven therapy (D group; n=60); MMP-3-driven therapy (M group; n=60); or both DAS28- and MMP-3-driven therapy group (Twin; T group; n=61). Specifically, medication was started with sulfasalazine (1 g/day) in all intervention groups. Targets were DAS28 <2.6 for D group, MMP-3 normalisation for M group, and both DAS28 <2.6 and MMP-3 normalisation for T group. If the value in question did not fall below the previously measured level, we intensified medication including methotrexate, other disease-modifying anti-rheumatic drugs and biologic agents. Primary, secondary, tertiary and quaternary outcome measures consisted of the proportions of patients in clinical remission (DAS28 <2.6), showing radiographic nonprogression (Dmodified total Sharp score 0.5), showing normal physical function (modified Health Assessment Questionnaire score=0), and comprehensive disease remission defined as the combination of clinical remission, radiographic nonprogression, and structural normal physical function.

    ResultsComprehensive disease remission at 56 weeks was achieved by more patients in T group (34%) than in R group (p<0.001), D group (p<0.05), or M group (p<0.001).

    Conclusion Results of the T-4 study revealed that comprehensive disease remission is an achievable goal in early RA with more aggressive therapy.

     

     

    RA患者中基质金属蛋白酶3正常和疾病活动指数小于2.6的双重达标比单一达标疗效更好:T-4双标准研究

    Yukitomo Urata , et al. ACR 2011. Present No: 1207

    背景/目的:评估在早期RA患者治疗56周的T-4研究中,DAS28< 2.6和基质金属蛋白酶3(MMP)3正常化的同时达标是否比单一达标的疗效更好。

    方法:243例早期RA患者随机分配到四个治疗组:常规治疗组(R;n = 62);DAS28-目标组(D;60);MMP-3-目标组(M;60),DAS28MMP-3双目标组(双标准,T;n = 61)。具体而言,所有干预组都从硫氮磺氨吡碇开始(1 g /) 。目标为DDAS28< 2.6,MMMP-3正常化,T组同时满足上述两个条件。如果测量值未达到上述标准,就需要强化治疗药物包括甲氨喋呤治疗、其它抗风湿病药和生物制剂第一、二、三级和四级疗效评价标准包括:临床缓解(DAS28< 2.6),放射学无进展 (改良的总Sharp积分≤0.5), 正常生理功能(改良的健康评估问卷得分= 0), 疾病全面缓解(为临床、影像学、和结构功能正常的综合评估)的患者比例。

    结果:56周时达到全面缓解的患者比例在T组为34%,明显高于R(p < 0.001),D(p < 0.05),M(p < 0.001)

    结论: T-4研究结果显示, 更积极的治疗完全可以使早期RA达到疾病全面缓解。

  • 相关阅读:
    JAVA规则引擎 -- Drools
    Spring多数据源的配置和使用
    nginx反向代理与正向代理的区别
    优化你的java代码性能
    java 代码优化
    java常用的设计模式
    Java中的异常处理从概念到实例
    详解JVM工作原理和特点
    mysql性能优化-慢查询分析、优化索引和配置
    外网不能访问部署在虚机的NodeJs网站(80端口)
  • 原文地址:https://www.cnblogs.com/T2T4RD/p/5464215.html
Copyright © 2020-2023  润新知